Tandem Diabetes Care TNDM Change in net unrealized gain (loss) on derivative instruments
Change in net unrealized gain (loss) on derivative instruments at other companies
Other financials
Where this comes from
Reported directly by Tandem Diabetes Care in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent.
The official record: Tandem Diabetes Care’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tandem Diabetes Care's change in net unrealized gain (loss) on derivative instruments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tandem Diabetes Care's change in net unrealized gain (loss) on derivative instruments?
- Tandem Diabetes Care (TNDM) reported change in net unrealized gain (loss) on derivative instruments of $1.7M in Q1 2026.
- What does change in net unrealized gain (loss) on derivative instruments mean?
- This represents the change in the fair value of derivative instruments designated as cash flow hedges that are effective in offsetting variability in cash flows. It captures the impact of hedging activities on the company's equity position before these gains or losses are reclassified into earnings. Monitoring this metric allows investors to assess the effectiveness and impact of the company's risk management strategies regarding market volatility.